PL EN
REVIEW PAPER
Influence of the intestinal microbiota on the development of irritable bowel syndrome
 
 
More details
Hide details
1
Katedra Zdrowia Publicznego, Wydział Nauk o Zdrowiu, Uniwersytet Medyczny w Lublinie Kierownik: prof. dr hab. n. med. T. Kulik
 
 
Corresponding author
Ewa Dudzińska   

Katedra Zdrowia Publicznego Wydział Nauk o Zdrowiu Uniwersytet Medyczny w Lublinie tel.: +48 81 448 67 20, +48 81 448 67 22
 
 
Med Srod. 2016;19(3):70-76
 
KEYWORDS
ABSTRACT
The human intestinal microbiota is made up of trillions of microorganisms that are considered to be nonpathogenic. The microbiota functions in tandem with the host’s defences and the immune system to protect against pathogen colonisation and invasion. It also performs an essential metabolic function, acting as a source of essential nutrients and vitamins and aiding in the extraction of energy and nutrients, such as short-chain fatty acids (SCFA). Gut microbiota alterations are being increasingly recognized as an important factor in the pathogenesis and pathophysiology of irritable bowel syndrome (IBS). Irritable bowel syndrome is a disease with a complex and unknown etiology. It is a functional disease although many researchers regard it as chronic, due to the long duration or frequent recurrence. IBS is characterized by abdominal pain and disturbances in bowel habits (constipation and/or diarrhea), in the absence of pathological organic changes. Studies in recent years have shown a significant effect of the intestinal microflora and intestinal cerebrospinal axis in the pathogenesis of the disease. Modulation of th intestinal microflora using probiotics and the focus on the function of uncultured intestinal microbiota will offer new opportunities for treatment of patients with this syndrome. Research into the intestinal microflora (the properties of microorganisms) is a promising direction, allowing for further understanding and characterization of many bacteria responsible for the pathophysiology and symptoms of IBS. It is still an enigmatic disease of multifactorial etiology, which seems to be related in significant ways to the composition of the intestinal microbiota. Research on the use of probiotics and prebiotics in IBS should be continued in numerous, well-planned clinical trials in order to obtain the best results in reducing IBS symptoms
 
REFERENCES (39)
1.
Hayes PA, Fraher MH, Path FRC i wsp. Quigley, Irritable Bowel Syndrome: The Role of Food in Pathogenesis and Management, Gastroenterol Hepatol (NY) 2014 Mar;10(3): 164-174.
 
2.
Binek M. Mikrobiom człowieka – zdrowie i choroba. Post. Mikrobiol 2012;51,1:27-36.
 
3.
Gritz EC, Bhandari V. The Human Neonatal Gut Microbiome: A Brief Review. Front Pediatr 2015;3:17.
 
4.
Radwan P, Skrzydło-Radomańska B. Rola mikroflory jelitowej w zdrowiu i chorobie. Gastroenterologia Praktyczna (2) 2013:1-11.
 
5.
Carding S, Verbeke K, Vipond DT i wsp. Dysbiosis of the gut microbiota in disease. MicrobEcol Health Dis 2015;26: 10.3402/mehd.v26.26191.
 
6.
Ohman L, Simrén M. Intestinal microbiota and its role in irritable bowel syndrome (IBS), CurrGastroenterol Rep 2013 May;15(5):323.
 
7.
Bellini M, Gambaccini D, Stasi C i wsp. Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy, World J Gastroenterol 2014 Jul 21;20(27): 8807-8820.
 
8.
Rajilić-Stojanović M, Jonkers DM, Salonen A i wsp. Intestinal Microbiota And Diet in IBS: Causes, Consequences, or Epiphenomena? Am J Gastroenterol 2015 Feb;110(2):278- 287.
 
9.
Nehring P, Mrozikiewicz-Rakowska B, Krasnodębski P i wsp.: Zespół jelita drażliwego – nowe spojrzenie na etiopatogenezę, Przegląd Gastrologiczny 2011;6(1):17-22.
 
10.
Scott KP, Antoine JM, Midtvedt T i wsp. Manipulating the gut microbiota to maintain health and treat disease, Microbial Ecology in Health & Disease 2015.
 
11.
Lee BJ, Bak YT. Irritable Bowel Syndrome, Gut Microbiota and Probiotics. J Neurogastroenterol Motil 2011 July; 17(3): 252-266. Published online 2011 July 13. doi:10.5056/jnm. 2011.17.3.252.
 
12.
Dąbrowski A. (red). Wielka interna część II. Gastroenterologia, Warszawa wyd. Medical Tribune Polska 2011:294- 307.
 
13.
El-Salhy M, Gundersen D, Ostgaard H i wsp. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome, Dig Dis Sci 2012;57(4):873- 878.
 
14.
Qin HY, Xiao HT, Wu JC i wsp. Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats, World J Gastroenterol 2012;18(20):2481-2492.
 
15.
Marlicz W, Zawada I, Starzyńska T. Zespół nadwrażliwego jelita – nadwrażliwe jelito czy nadwrażliwy umysł? Pol Merk Lek 2012, XXXII, 187:64-69.
 
16.
Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome, PharmacolTher 2007;116(2):207-235.
 
17.
Zouiten ML, Karoui S, Boubaker J i wsp. The pathophysiology of irritable bowel syndrome, Tunis Med. 2006;84(5): 269-274.
 
18.
Ringel Y, Sperber AD, Drossman DA: Irritable bowel syndrome, Annual Review of Medicine 2001;52:319-338.
 
19.
Elsenbruch S, Rosenberger C, Enck P i wsp. Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study, Gut. 59, 2010:489-495.
 
20.
Dorn SD, Palsson OS, Thiwan SIM i wsp. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut. 2007 September; 56(9):1202- 1209.
 
21.
Elsenbruch S. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms, Brain Behav Immun 2011;25(3):386-394.
 
22.
Porro GB, Cremer M, Krejs G. i wsp. Gastroenterologia i hepatologia, Lublin wyd. Czelej 2003, p. 189.
 
23.
Katsinelos P, Lazaraki G, Kountouras J i wsp. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece, Eur J GastroenterolHepatol 2009;21(2):183-189.
 
24.
Palsson OS, Drossman DA: Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments, GastroenterolClin North Am 2005;34(2):281-303.
 
25.
Drossman DA, Morris CB, Schneck S i wsp. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit, J Clin Gastroenterol 2009;43(6):541-550.
 
26.
Cash BD, Chey WD. Diagnosis of irritable bowel syndrome, Gastroenterol Clin North Am 2005;34(2):205-220.
 
27.
Grundmann O, Yoon SL. Irritable bowel syndrome: Epidemiology, diagnosis and treatment: An update for health-care practitioners. J. Gastroenterol. Hepatol 2010;25(4):691-699.
 
28.
Mahvi-Shirazi M, Fathi-Ashtiani A, Rasoolzade-Tabatabaei SK i wsp. Irritable bowel syndrome treatment: cognitive behavioral therapy versus medical treatment, Arch Med Sci 2012;29,8(1):123-129.
 
29.
Lackner JM, Lou Coad M, Mertz HR i wsp. Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety, Behaviour Research And Therapy 2006;44(5):621-638.
 
30.
Kuttner L, Chambers ChT, Hardial J i wsp. A randomized trial of yoga for adolescents with irritable bowel syndrome, Pain Research & Management. vol. 11(4)2006:217-223.
 
31.
El-Salhy M, Ostgaard H, Gundersen D i wsp. The role of diet in the pathogenesis and management of irritable bowel syndrome (Review), Int J Mol Med 2012;29(5):723-731.
 
32.
Ghoshal UC, Shukla R, Ghoshal U i wsp. The gut microbiota and irritable bowel syndrome: friend or foe?, Int J Inflam. 2012;2012:151-85.
 
33.
Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014 Jul 21;20(27):8886-97.
 
34.
Dlugosz A, Winckler B, Lundin E i wsp. No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. Sci Rep. 2015 Feb 17;5:8508.
 
35.
Shukla R, Ghoshal U, Dhole TN i wsp. Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis. Dig Dis Sci 2015 Mar 18.
 
36.
González T, Gonzalez S, Madiedo R i wsp. Irritable Bowel Syndrome; gut microbiota and probiotic therapy, Nutr Hosp. 2015 Feb 7;31 Suppl 1:83-8.
 
37.
Evangelista S. Benefits from long-term treatment in irritable bowel syndrome, Gastroenterol Res Pract 2012;2012:936- 960.
 
38.
Gerson MJ, Gerson CD. The importance of relationships in patients with irritable bowel syndrome: a review, Gastroenterol Res Pract 2012;2012:157-340.
 
39.
Luscombe FA. Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review, Qual Life Res 2000;9(2):161-167.
 
eISSN:2084-6312
ISSN:1505-7054
Journals System - logo
Scroll to top